CytomX Therapeutics (CTMX) Reports Q1 Loss, Lags Revenue Estimates

10:25pm, Thursday, 05'th May 2022 Zacks Investment Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -5.71% and 21.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Patient enrollment completed in Arm A in the Phase 2 study of praluzatamab ravtansine in breast cancer, initial data for both Arms A and B on track for second half of 2022 -
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that i
SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that
SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that
SOUTH SAN FRANCISCO, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that p

CytomX stock soars 16% as Q4 revenue rises 20% Y/Y

06:43pm, Wednesday, 02'nd Mar 2022 Seeking Alpha
CytomX Therapeutics <> rose following its FY21 results, which missed on analysts'' estimates.Q4 total revenues rose 20.2% Y/Y to $19.7M. The increase Q4 revenue was largely related…
Gainers: Organogenesis (ORGO) +24%. CytomX Therapeutics (CTMX) +13%. X4 Pharmaceuticals (XFOR) +13%
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label To Include Advanced Endome

CytomX Therapeutics (CTMX) Q4 2021 Earnings Call Transcript

06:00am, Wednesday, 02'nd Mar 2022 The Motley Fool
CTMX earnings call for the period ending December 31, 2021.

CytomX Therapeutics (CTMX) Q4 2021 Earnings Call Transcript

06:00am, Wednesday, 02'nd Mar 2022 The Motley Fool
CTMX earnings call for the period ending December 31, 2021.
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q4 2021 Results - Earnings Call Transcript
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE